Abstract: Hetrombopag olamine (hetrombopag) is a novel small-molecule, orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist that is being developed as the treatment for thrombocytopenia. Two randomized, placebo-controlled phase I studies were conducted in 72 healthy individuals to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hetrombopag. Hetrombopag was orally administered with a single dose in five dose cohorts (5 mg, 10 mg, 20 mg, 30 mg or 40 mg) in the first study, and given once daily for 10 days in three dose cohorts (2.5 mg, 5.0 mg or 7.5 mg) in the second study, respectively. Hetrombopag was well tolerated, and the majority of adverse events associated with medicine were platelet elevations significantly above the normal range in healthy individuals. The single dose-escalation study revealed a T max of approximate 8 hr, and a t 1/2 of 11.9 hr to 40.1 hr in a dose-prolonged manner. A dose-proportional increase in maximum concentration (C max ) of hetrombopag was observed, with area under the curve (AUC) increasing in a greater than dose-proportional manner. The plasma concentration of hetrombopag reached the steady-state after 7 days. The steady-state AUC 0-24 hr and C max were dose-proportionally elevated from the 5.0 mg to 7.5 mg dose level. The potent pharmacological effect of the hetrombopaginduced platelet elevation was observed in a time-and dose-dependent manner. Furthermore, the thrombopoietic response was significantly (p < 0.0001) correlated to the plasma exposure level of hetrombopag in single and multiple administration studies. Taken together, results of this study support further clinical development of hetrombopag in patients with thrombocytopenia.
Serious event from thrombocytopenia, such as bleeding after surgery, gastrointestinal bleeding and central nervous system haemorrhage, is a challenge for clinicians. Although thrombocytopenia can be induced by primary immune thrombocytopenia (ITP), aplastic anaemia, cirrhosis, chemotherapy-induced thrombocytopenia (CIT) and other immune system abnormalities, a decreased platelet count is the common feature.
Most traditional treatments for thrombocytopenia are primarily to reduce platelet destruction and deliver a platelet transfusion. However, the discovery of thrombopoietin (TPO) [1] [2] [3] and TPO receptor (TPO-R, c-Mpl) has changed the clinical treatment landscape of thrombocytopenia. TPO binding to its receptor activates the cytoplasmic tyrosine kinases Janus kinase 2 (JAK2) and tyrosine kinase 2 (TyK2) [4] [5] [6] , which results in enhanced megakaryocyte proliferation, differentiation and ultimately platelet production. Therefore, compounds that act in a similar manner as TPO have become a novel promising therapeutic agents for treating thrombocytopenia [7] [8] [9] . TPO-R agonists, such as eltrombopag (a first small-molecule TPO-R agonist) [10] and romiplostim (an Fc-peptide fusion protein) [11] , have been approved by the FDA and the European Medicines Agency for the treatment of thrombocytopenia in patients with chronic ITP. However, subcutaneous administration of romiplostim and the hepatotoxicity of eltrombopag are inconvenient for patients. Furthermore, these drugs are usually expensive or unavailable to patients in China. Therefore, new treatments are required.
Hetrombopag olamine (hetrombopag) is a novel small-molecule, non-peptide TPO-R agonist that has been developed by a Chinese pharmaceutical company, Jiangsu Hengrui Medicine Co., LTD. Pre-clinical studies demonstrated that the mechanism of action of hetrombopag was similar to that of eltrombopag, but its in vivo pharmacological effect was 8-10 stronger than eltrombopag (unpublished data).
Our studies aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeated administrations of hetrombopag in healthy individuals. This investigation in healthy individuals was also intended to establish the optimal dose range for subsequent studies in patients with thrombocytopenia.
Methods

Clinical study design.
Two phase 1 studies (study A and study B) consisted of a double-blind (to site staff, patients and sponsor), randomized, placebo-controlled, dose-escalation study designed to evaluate safety, pharmacokinetic and pharmacodynamic profiles of hetrombopag in Chinese healthy male individuals. All individuals Author for correspondence: Li Zheng, Institute of Clinical Pharmacology/GCP Center, West China Hospital of Sichuan University, Guoxuexiang 37#, Chengdu, China (e-mail lzheng2005618@163.com). *These authors contributed equally to this work received oral hetrombopag or placebo as tablets after a 12-hr over-night fasting. Doses were escalated after one another sequentially after review of available safety data. Each individual only participated in one dose cohort. Intensive safety, tolerability, pharmacokinetics and pharmacodynamic assessments were carried out throughout the study period.
The study was conducted at West China Hospital, Chengdu, China, according to Good Clinical Practice (GCP) and in accordance with the principles of the Declaration of Helsinki (1996) . The study protocols were approved by the institutional ethics committee (Approval Number WCHIEC 20120030). This trial was registered at www.clinicaltrials.gov as #NCT01830660. All individuals provided informed consent before enrolment.
Thirty-six eligible individuals were enrolled in study A from 24 April 2012 to 4 January 2013, and 36 individuals were enrolled in study B from 30 November 2012 to 11 April 2013. A randomization code list for assigning randomization numbers to treatment with hetrombopag or placebo was prepared by the Biometric Department.
Study A.
In the first-in-human study, 36 healthy male individuals were randomized to orally receive a single dose of hetrombopag or placebo. Five cohorts of hetrombopag were 5.0 mg (1 9 5 mg), 10 mg (2 9 5 mg), 20 mg (4 9 5 mg or 1 9 20 mg), 30 mg (2 9 5 mg + 1 9 20 mg) and 40 mg (2 9 20 mg). Each dose was investigated in a group of six individuals (five on hetrombopag and one on placebo). Plasma samples for PK analysis were collected before dosing and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96 and 120 hr after hetrombopag administration.
Study B.
Thirty-six healthy male individuals were randomized into three dose (2.5 mg, 5 mg or 7.5 mg) cohorts to receive hetrombopag (10 individuals) or placebo (two individuals) in each cohort once daily for 10 days. Plasma samples for PK analysis were collected before dosing and after the administration of hetrombopag at 0.5, 1, 2, 4, 6, 7, 8, 10, 12, 24 hr on day 1, before dosing on days 7, 8, 9 and 10, and 0.5, 1, 2, 4, 6, 7, 8, 10, 12, 24, 48, 72, 96 and 120 hr after dosing on day 10.
Individuals.
Healthy male Chinese individuals aged 18-45 years with body-weights greater than 50 kg and body mass indexes from 19 to 28 kg/m 2 were eligible for these studies. All individuals were judged healthy based on findings of medical history, physical examination, laboratory tests and electrocardiogram (ECG). Individuals were excluded if they had been treated with an investigational drug within the past 3 months, a history of alcohol abuse within 6 months, or smoking more than five cigarettes daily. Individuals were not included if they were tested positive for hepatitis (B or C) or HIV and had a history of myocardial infarction, deep vein thrombosis, thrombocytopenia or clotting-factor abnormalities. Further, individuals were excluded if they were unwilling to use appropriate effective contraception.
Safety, pharmacokinetic and pharmacodynamic assessments. Safety, tolerability, pharmacokinetic and pharmacodynamic assessments were performed according to the protocols throughout the study. Safety and tolerability were evaluated by monitoring adverse events, vital signs, physical examination, ECG, ophthalmological examination and clinical laboratory variables including serum chemistries, haematology, urinalysis and blood clotting tests. Pharmacodynamic parameters included platelet count (studies A and B), platelet activation (study B) and platelet aggregation (study B). Platelet activation was assessed using a Becton Dickinson flow cytometer to measure the percentage of PAC-1 and P-selectin-positive platelets. The PACKS-4 system (Helena Labs, Beaumont, TX, USA) was used to measure platelet aggregation in the presence of ADP as an agonist.
Determination of hetrombopag concentrations in plasma was conducted using the LC-MS/MS method by WuXiAppTec Company in Shanghai, China. An analytical method for the determination of hetrombopag in plasma was developed and validated over the concentration ranges of 2-1000 ng/ml (except the 2.5 mg group) and 0.5-150 ng/ml for the 2.5-mg group in study B. The analyses were isolated using protein precipitation extraction in a 96-well format with a 100 ll of acidified plasma sample fortified with 50 ll of a stable isotopelabelled internal standard (Everolimus, Provided by TRC). An aliquot of the supernatant was analysed using reverse-phase high-performance liquid chromatography (Acquity UPLC; Waters, Milford, MA, USA) with a tandem mass spectrometric detection system (Applied Biosystems Sciex, Concord, ON, Canada). Multiple-reaction monitoring of the precursor to product ion pairs was used for quantification. The mean correlation coefficient (R 2 ) for hetrombopag was 0.9956. The intraday and interday coefficients of variation were ≤4.8% and ≤7.2%, respectively, for hetrombopag across all standard concentrations.
Data and statistical analysis. The pharmacokinetics of hetrombopag was estimated using the non-compartmental analysis in Pheonix WinNonlin 6.1 (Pharsight, Mountain View, CA, USA). Concentrations of hetrombopag in plasma and nominal sampling times were used to estimate pharmacokinetic parameters in each individual. The area under the plasma concentration-time curve (AUC) was calculated using the linear trapezoidal method for ascending concentrations, and the log trapezoidal method was used for descending concentrations. The extrapolated portion of the AUC from the last time-point of sample collection (t last ) to infinity was determined by dividing the observed concentration at t last (C last ) by the terminal rate constant (k e ). AUC 0-∞ was calculated from the sum of the AUC through the last measured time-point (AUC last ) and the extrapolated area. The value of k was determined from the slope of a least-squares fit to the terminal phase of the log-transformed concentrationtime curve. The t 1/2 was calculated from the equation t 1/2 = ln (2)/k e . The observed maximum plasma concentration (C max ) and time to reach C max (T max ) were obtained by the plasma concentration-time data. The geometric mean and coefficient of variation (CV) for each parameter were calculated.
The observed accumulation ratio (R) was defined as steadystate AUC 0-24 hr /first-dose AUC 0-24 hr . The observed accumulation ratio and their associated 90% confidence intervals (CIs) were estimated by fitting separate analyses of covariance models for first-dose AUC 0-24 hr and steady-state AUC 0-24 hr after log transformation, including day as a fixed effect and volunteer as a random effect in each model.
An assessment of dose proportionality with exposure levels was performed using log-transformed AUC 0-t and C max data with the power model, and a slope of 1 was considered as dose proportionality.
Statistical analyses of the safety and pharmacodynamic data were performed with the SAS Statistical Package, version 9.3 (SAS Research and Development Co., Ltd, Chapel Hill, NC, USA). Tests of statistical hypotheses were performed at the 5% significance level.
The co-relationships between the best platelet response (maximum percentage increase from baseline) and C max and AUC 0-t were analysed to obtain correlation coefficient (r) values using linear regression fitting in Origin 8. p < 0.05 was considered statistically significant.
Results
Individual demographics.
A total of 72 healthy male individuals were eligible and enrolled in these studies.
Safety and tolerability.
Hetrombopag were generally safe and well tolerated in healthy individuals in both studies. There were limited adverse events (AEs), occurring in 4 of 36 individuals (11.1%) in study A and 6 of 36 individuals (16.7%) in study B. As shown in table 1, the platelet count elevations accounted for the majority of adverse events. Besides platelet increase, the AEs related to the study medication included dizziness, headache, eye discomfort and fatigue, and all were grade I (CTCAE 3.0).
All AEs were judged as grades 1 or 2 by the study investigator. Only one individual in the 7.5 mg group discontinued hetrombopag administration (day 8) due to a platelet count >400 9 10 9 /L (day 7) according to the protocol requirement. In study B, 6 of 11 individuals with AE of platelet increases (2 individuals in 5 mg; 4 individuals in 7.5 mg) received aspirin to decrease the potential of thrombosis. Aspirin treatment for those individuals started around day 10 (day 7 -day 14) and completed around day 16 (day 11 -day 31).
The other AEs not related to hetrombopag included infectious coryza, diarrhoea and sore throat; all were grade 1 and resolved without concomitant medication. There were no other clinical significant changes in laboratory tests, vital signs, physical examination and ECG recordings. No serious AEs were reported in both studies.
Pharmacokinetics.
Plasma pharmacokinetic parameters of hetrombopag after single dosing (study A) and 10-day repeated dosing (study B) are presented in table 2.
Plasma concentrations were quantifiable within 0.5-2 hr after a single dose of hetrombopag in study A. The double peaks of hetrombopag concentration-time course were observed in the study. As shown in fig. 1A , the first peak was 1-2 hr, and the second peak occurred 8-10 hr after dosing. The median T max value of all dose levels was 8 hr after dosing. Hetrombopag was slowly eliminated with a geometric mean of t 1/2 ranging from 11.9 to 40.1 hr (table 2) in a doseprolonged manner, with a longer elimination half-life as the All values are n (%). Data are presented as the geometric means (% coefficient of variation, 95% confidence interval) or meanAESD, except for T max , which is presented as the median (minimum, maximum).
dose increased. The C max of hetrombopag was increased in a dose-proportional manner (b = 0.98), while AUC 0-t was increased in a greater than dose-proportional manner (b = 1.42) after a single dosing from 5.0 mg to 40 mg. In study B, similar double peaks of hetrombopag concentration were observed in the majority of individuals at all dose levels after the first dose of hetrombopag on day 1. Consistent with data in study A, the first peak occurred after 1-2 hr, and the second peak occurred 7-8 hr after the first administration ( fig. 2) .
The plasma concentration reached the steady-state on day 7 after once-daily administration of hetrombopag. After reaching the steady-state by daily dosing, from the 2.5 mg to 5 mg dose level, AUC 0-24 hr and C max were increased in noproportionality, but between the 5.0 mg and 7.5 mg dose level, they were linearly increased (table 2) . A high variability in pharmacokinetic parameters among individuals receiving the same dose of hetrombopag was found for C max and AUC 0-t on day 10. The mean (minimum-maximum) of maximum percentage increases in platelet count from baseline was 7.1%, 34.1%, 69.9% and 98.2% for the placebo, 2.5-mg, 5.0-mg and 7.5-mg hetrombopag groups, respectively ( fig. 3A,B) . Platelet counts above the 400 9 10 9 /L level were observed in 4 of 10 individuals in the 7.5-mg group, 2 of 10 individuals in the 5.0-mg group and none in the 2.5-mg group. The platelet count peaking above the 500 9 10 9 /L level was found in three individuals and all occurred in the 7.5-mg group.
Platelet function. Platelet function was measured using platelet activation and aggregation assays after repeated administrations of hetrombopag, and data are summarized in table 3 . Platelet activation, the mean positive expression rates of PAC-1 and CD62P, was affected by the 10-day hetrombopag administration. The mean PAC-1-positive rate was significantly decreased in the 7.5-mg group on day 14 and day 28 (p = 0.03 and p = 0.01, respectively), and slightly decreased in the 2.5-mg and 5.0-mg groups on day 14 (p > 0.05). The mean percentage of CD62P-positive platelets was significantly decreased on day 14 (4 days after hetrombopag discontinuation) in all dose groups and returned to baseline on day 28 (18 days after hetrombopag discontinuation). In contrast, there was no notable change in PAC-1-positive and CD62P-positive platelets after placebo treatment. However, platelet aggregation was not affected after the treatment of either placebo or hetrombopag.
Plasma exposure-platelet response relationship. The PK-PD correlation analysis was performed to assess the relationship between the plasma exposure of hetrombopag and its effect on the platelet elevation.
The maximum elevation of platelet counts from individuals across all dose levels was statistically correlated to the plasma exposure of hetrombopag with the C max (r = 0.84, p < 0.0001, fig. 4A ) and AUC 0-t (r = 0.68, p < 0.0001, fig. 4B ) after the single-dose administration.
Consistent with data from study A, the maximum elevation of platelet counts from individuals across all dose levels was correlated with the plasma exposure with the C max (r = 0.67, p < 0.0001, fig. 4C ) and AUC 0-t (r = 0.67, p < 0.0001, fig. 4D ) after 10 days of once-daily dosing with hetrombopag in study B.
Discussion
This first-in-human study provides promising results of hetrombopag, a novel small-molecule, orally bioavailable thrombopoietin receptor agonist.
Single-dose administration of hetrombopag up to 40 mg and 10-day administrations of hetrombopag up to 7.5 mg were generally safe and well tolerated in healthy individuals. There were limited adverse events, and elevation of platelet counts accounted for the majority of adverse events in the present study. The adverse events (AEs) related to the study medication also included mild dizziness, headache, eye discomfort and fatigue, and occurred along with significantly increased platelet counts above the normal range. Similar findings of headache and dizziness were also reported in previous studies of romiplostim [12] [13] [14] [15] and eltrombopag [13] [14] [15] [16] [17] [18] . In the eltrombopag study [13] [14] [15] [16] [17] [18] , a 2-4% elevation of aminotransferase was found; individual individuals had an interruption of treatment due to liver toxicity. But in the present study, no clinically significant abnormalities in hepatobiliary laboratory tests were found, which was consistent with pre-clinical findings of hetrombopag.
The clinically significant elevation of platelet counts above the normal range was found to be the only AE of laboratory tests in the study. The AEs caused by the pharmacological effect of hetrombopag occurred in 10 individuals in study A (80%, 100% of individuals in the 30-mg and 40-mg group, respectively) and 11 individuals in study B (30.0% and 70.0% of individuals in the 5-mg and 7.5-mg group, respectively), indicating that the incidence was dose-dependent (table 1) .
In this study, the AUC 0-t was increased in a greater than dose-proportional manner (b = 1.42) after a single dosing from 5.0 mg to 40 mg. Further analysis showed that in the range of 5-20 mg, AUC 0-t was increased in a dose-proportional manner (b = 0.91). The pharmacokinetic profile indicated that hetrombopag was slowly eliminated with a t 1/2 of 11.9 to 40.1 hr, and a delay in drug elimination may increase the plasma exposure to the drug. Double peaks were observed Fig. 3 . Mean change of platelet count from baseline versus time for placebo and hetrombopag treatment groups for platelet count value (10 in hetrombopag concentration-time profiles, with a smaller peak (1-2 hr) and a second large peak (7-10 hr). The results of metabolite analyses in animals demonstrated that glucuronide of hetrombopag was observed in the plasma, bile and faeces. The glucuronide conjugation of hetrombopag is likely excreted with bile acid and subsequently hydrolysed into aglycone in the intestinal tract where it is re-absorbed. Therefore, the enterohepatic circulation may be one of the reasons for the slow elimination and the double-peak concentration curve of hetrombopag.
The AUC 0-24 hr ratio between day 10 and day 1 were 1.14, 1.63 and 1.99, showing that the hetrombopag exposure increased for the 2.5 mg, 5.0 mg and 7.5 mg level, respectively. Similar results of eltrombopag in healthy individuals indicated an accumulation of 40-50% with 20-75 mg eltrombopag administration for 10 days [19] , and average increases of 66-81% for AUC 0-t in 100-200 mg doses of eltrombopag administration for 5 days [20] .
In addition, Wire et al. reported the intersubject variability in plasma C max and AUC 0-t of eltrombopag with % CV values of 37% to 57% in healthy individuals [21] . A high variability in pharmacokinetic parameters of hetrombopag among individuals who received the same dose was also found with a % CV of 40.7-61.9% for C max and % CV of 60.2-83.6% for AUC 0-t at steady-state. The preclinical data suggested that hetrombopag was mainly exhausted by the faeces (89.5%), and the main metabolites were the prototype drugs and glucuronic acid metabolites (unpublished data). Whether the polymorphism of the glucuronyl transferase or microenvironment of absorption locations has an effect on drug metabolism, variability in PK parameters and the correlational effect remains to be further studied. Despite the intersubject variability in pharmacokinetic parameters, the PK-PD correlation profile of hetrombopag suggested that the optimal pharmacological effects could be achieved with modifications of doses during treatment in individual patients by monitoring platelet count.
The maximum increases in platelet counts after repeat eltrombopag treatment were 24.1%, 42.9% and 50.4% for 30 mg, 50 mg and 75 mg, respectively, in healthy male individuals [19] . The platelet count was returned to baseline values after dose discontinuation (12 days after the last dose of eltrombopag). In the present study, the effects on platelet elevation induced by hetrombopag treatment were dosedependent and time-dependent. In comparison, hetrombopag in a dose range of 2.5-7.5 mg exhibited comparable or higher responses and longer time course than eltrombopag in the dose range of 30-75 mg. Considering different races, hetrombopag is at least 5 times more potent than eltrombopag in increasing platelet counts in healthy individuals. Furthermore, low doses of hetrombopag achieving a comparable pharmacological effect might reduce the potential of off-target toxicity.
Our study also assessed the effect of hetrombopag on platelet activation and aggregation after administration. Platelet activation and aggregation are the important processes for the haemostasis in the coagulation pathway. PAC-1 and CD62P are the most specific biomarkers during the platelet activation process [22, 23] . Platelet activation will release adenosine diphosphate (ADP) and other particles that assist in platelet binding to fibrinogen and trigger platelet aggregation. Platelets facilitate blood clot formation by an increase in the platelet aggregation rate [24] . Although TPO primes platelets for activation in vitro, eltrombopag does not demonstrate an equivalent effect on platelet activation and aggregation in vitro and in healthy individuals [19, 25] . Our study demonstrated a lower platelet activation rate after hetrombopag treatment for 10 days in healthy individuals. One of the possible reasons may be the feedback inhibition mechanism that prevents thrombosis by lowering platelet activation along with elevated platelet levels in healthy individuals. Another reason may be due to aspirin concomitant medication in individuals who experienced significant increase in platelet Table 3 . Positive expression rates of platelet activation and aggregation for baseline, day 14 and day 28 in study B numbers, as it has been found that aspirin inhibits glycoprotein CD62P and PAC-1 expression in platelets [26, 27] . In the present study, 6 of the 11 individuals with AE of platelets significantly above a normal range received aspirin to decrease the potential risk of thrombosis, which may have an effect on the activation rate of platelets during the study. Moreover, all doses of hetrombopag did not affect the aggregation function of platelets in healthy individuals, implicating that hetrombopag has no effect on the downstream event from the platelet activation.
Conclusion
In summary, this study demonstrated that hetrombopag was safe and well tolerated in healthy individuals with potent thrombopoietic activity and acceptable pharmacokinetic profiles. A dose range of 2.5-7.5 mg once daily could be considered a recommended regimen for future studies in patients with chronic immune thrombocytopenia.
